Eli Lilly and Company announced plans to construct a $6.5 billion state-of-the-art manufacturing facility at Generation Park in Houston, Texas. This new site will focus on producing synthetic medicine active pharmaceutical ingredients (APIs) for Lilly’s pipeline of small molecule drugs across several therapeutic areas including cardiometabolic health, oncology, immunology, and neuroscience. The facility is expected to be operational within five years and marks the second of four new U.S. manufacturing sites Lilly plans to unveil this year.
The Houston facility will create 615 high-wage jobs for skilled professionals such as engineers, scientists, operations personnel, and lab technicians. During construction, the project is also expected to generate around 4,000 jobs. Among its key manufacturing priorities will be orforglipron, Lilly’s first oral small molecule GLP-1 receptor agonist for obesity, which the company plans to submit for global regulatory approval by the end of this year.
David A. Ricks, Lilly’s chair and CEO, emphasized that the Houston site will enhance the company’s ability to produce orforglipron at scale, ensuring quicker and more secure access to this and future medicines. The investment also represents a significant move to onshore API production in the U.S., strengthening Lilly’s manufacturing footprint domestically.
Lilly had previously announced plans earlier this year to expand domestic medicine production with four new pharmaceutical manufacturing sites, with one location recently confirmed in Virginia and two more yet to be revealed.
The new facility is poised to provide a substantial boost to Houston’s economy. Lilly estimates that every dollar spent locally will stimulate up to four additional dollars in the regional economy, with a ripple effect creating jobs in related sectors such as supply chain, logistics, and retail.
Texas Governor Greg Abbott praised the investment as one of the largest pharmaceutical manufacturing projects in U.S. history, highlighting Texas’s business-friendly environment, skilled workforce, and position as a leader in health care innovation.
The facility will incorporate cutting-edge technologies including machine learning, artificial intelligence, digitally integrated systems, and advanced data analytics to optimize manufacturing processes. Digital automation will be embedded throughout operations to ensure consistent production of safe, high-quality medicines. Lilly also plans to partner with local universities and invest in educational programs to build a strong talent pipeline in Texas.
Edgardo Hernandez, Lilly’s executive vice president and president of Lilly Manufacturing Operations, said the new chemical synthesis facility will expand advanced pharmaceutical capabilities in the U.S. and set a new global standard for innovation and technical leadership, while maintaining a commitment to sustainability and community support.
Generation Park in the Lake Houston area was selected from over 300 applicants based on factors such as workforce availability, local incentives, access to utilities and transportation, and a favorable business climate. The scale of Lilly’s investment and job creation surpasses initial commitments made during the Texas incentive process, underscoring the critical role the site will play in enhancing Lilly’s global medicine production capacity.